Floatz logo

Fenofibrate

Metabolic X Syndrome Dyslipidemia

Merck Sharp & Dohme LLCSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Metabolic X Syndrome Dyslipidemia cohort.

Asset / SponsorPhaseRating
MK-0767
Merck Sharp & Dohme LLC
Phase 2CCC

Same molecule, other indications

Fenofibrate is also rated in:

inherited lipid metabolism disorderDormant
BBB
Indicative ·
74 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
71 / 100
View asset →
hypertriglyceridemiaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →